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ML-IAP, a novel inhibitor of apoptosis that is preferentially
expressed in human melanomas
Domagoj Vucic*, Henning R. Stennicke†, Maria Teresa Pisabarro‡,
Guy S. Salvesen† and Vishva M. Dixit*
Background: Inhibitors of apoptosis (IAPs) are a family of cell death inhibitors
found in viruses and metazoans. All IAPs have at least one baculovirus IAP
repeat (BIR) motif that is essential for their anti-apoptotic activity. IAPs
physically interact with a variety of pro-apoptotic proteins and inhibit apoptosis
induced by diverse stimuli. This allows them to function as sensors and
inhibitors of death signals that emanate from a variety of pathways.
Results: Here we report the characterization of ML-IAP, a novel human IAP that
contains a single BIR and RING finger motif. ML-IAP is a powerful inhibitor of
apoptosis induced by death receptors and chemotherapeutic agents, probably
functioning as a direct inhibitor of downstream effector caspases. Modeling
studies of the structure of the BIR domain revealed it to closely resemble the
fold determined for the BIR2 domain of X-IAP. Deletion and mutational analysis
demonstrated that integrity of the BIR domain was required for anti-apoptotic
function. Tissue survey analysis showed expression in a number of embryonic
tissues and tumor cell lines. In particular, the majority of melanoma cell lines
expressed high levels of ML-IAP in contrast to primary melanocytes, which
expressed undetectable levels. These melanoma cells were significantly more
resistant to drug-induced apoptosis.
Conclusions: ML-IAP, a novel human IAP, inhibits apoptosis induced by death
receptors and chemotherapeutic agents. The BIR of ML-IAP possesses an
evolutionarily conserved fold that is necessary for anti-apoptotic activity. Elevated
expression of ML-IAP renders melanoma cells resistant to apoptotic stimuli and
thereby potentially contributes to the pathogenesis of this malignancy.
Background
Apoptosis is a cell suicide mechanism with a major role in
development and homeostasis in vertebrates and inverte-
brates [1]. Dysregulation of apoptosis leading to early cell
death or the absence of normal cell death contributes to a
number of disease states including neurodegenerative
disorders and cancer [2]. It is becoming evident that inhi-
bition of apoptosis enhances the survival of cancer cells
and facilitates their escape from immune surveillance and
cytotoxic therapies. Among the principal molecules con-
tributing to this phenomenon are inhibitors of apoptosis
(IAPs) [3].
IAPs were originally identified in baculoviruses by their
ability to substitute functionally for the powerful anti-
apoptotic P35 viral gene product [4–6]. Subsequently,
homologs of IAPs have been discovered in both inverte-
brates and vertebrates [3,7–15]. Members of the IAP
family are characterized by the presence of at least one,
and usually two or three, tandem baculovirus IAP repeat
(BIR) motifs. In addition, most also possess a carboxy-ter-
minal RING finger motif [16]. IAPs interact with multiple
cellular partners and inhibit apoptosis induced by a variety
of stimuli [3]. For example, baculovirus Op-IAP and Cp-IAP
and Drosophila D-IAP1 and D-IAP2 bind and inhibit
apoptosis induced by Reaper, Hid, and Grim, which are
the principal developmental inducers of apoptosis in the
fly [17,18].
The anti-apoptotic activity of some IAPs has been attrib-
uted to their ability to inhibit caspases [19–21], which are
cysteine-dependent aspartate-specific proteases that com-
prise the effector arm of the cell death pathway [22]. For
instance, X-IAP, C-IAP1, and C-IAP2 inhibit active cas-
pases 3 and 7 and the Apaf-1–cytochrome-c-mediated acti-
vation of caspase-9 [23–25]. Some IAPs are not involved in
cell death, however, but are instead involved in regulating
the cell cycle. These are exemplified by human survivin, a
RING-less IAP which is expressed in the G2–M phase of
the cell cycle and localizes to mitotic spindle microtubules
where it influences mitotic progression [26,27]. Survivin has
a striking pattern of expression as its transcript is found in
many cancers and in fetal, but not adult, differentiated
tissues [14,28]. Here we describe a new human IAP,
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ML-IAP, whose expression, like that of survivin, is markedly
increased in many transformed cells and embryonic
tissues. Notably, the majority of melanoma cell lines over-
express ML-IAP. As we show ML-IAP to be a potent
inhibitor of apoptosis induced by engagement of death
receptors and exposure to tumoricidal drugs, its over-
expression may have an important role in the evolution of
this and other malignancies.
Results
ML-IAP is a new member of the IAP family
Search of the LifeSeq database (Incyte Pharmaceuticals)
for sequences homologous to IAP family members identi-
fied a previously unknown human sequence related to the
BIR domain. Sequence analysis revealed two almost iden-
tical cDNAs that differed only by the presence of an extra
54 nucleotides. Both cDNAs encoded predicted proteins,
of 280 and 298 amino acids respectively, containing a
single BIR and RING finger motif characteristic of the
IAP family (Figure 1a). The 18 amino acids that differen-
tiate these two proteins are located between the BIR and
the RING finger motifs (Figure 1a). We used the shorter
form in the majority of experiments as no functional dif-
ference was discernible between these two forms (see
below). Protein sequence alignments demonstrated signif-
icant homology of the ML-IAP BIR and RING finger
motifs to corresponding motifs present in human X-IAP,
C-IAP1 and C-IAP2 (Figure 1b,c). The BIR motif of
ML-IAP appears to be most similar to the central (second)
and carboxy-terminal (third) BIRs of X-IAP, C-IAP1 and
C-IAP2 (Figure 1b) and may represent a hybrid of these
two BIR subgroups [29].
Expression of ML-IAP transcript was assessed by northern
blot analysis. It revealed two mRNA species of 1.5 and
2.2 kb in size that arise from probable use of alternative
polyadenylation signals present in the 3′ untranslated region.
The strongest signal was detected in melanoma cell lines
but also in some lymphomas, fetal kidney, fetal liver,
testis and thymus (Figure 1d). Given the elevated expres-
sion in melanoma cell lines (Figures 1d,7), we termed this
new IAP family member ML-IAP for melanoma IAP. In
keeping with a potential role in cancer, the genomic locus
for ML-IAP mapped to a region (chromosome 20q13) that
is frequently amplified in melanomas and colon, lung, and
colorectal malignancies [30–32].
As survivin, another cancer-associated IAP, localizes to
mitotic spindles, we determined the subcellular localiza-
tion of ML-IAP. As evident from Figure 1e, ML-IAP and
its RING finger localized predominantly to the cyto-
plasm of MCF7 breast cancer cells and not to mitotic
1360 Current Biology Vol 10 No 21
Figure 1
(a) Deduced amino acid sequence of ML-IAP.
The open reading frame for ML-IAP reveals
the presence of a single BIR domain and the
RING finger (both underlined). The boxed
area represents the difference between
isolated ML-IAP cDNAs. Amino acid
sequence alignments of (b) BIR and (c) RING
finger domains from human IAPs. (d) Tissue
distribution of the ML-IAP mRNA. Human
adult and fetal multiple-tissue and cancer cell
line northern blots (Clontech) were probed
with an internal fragment of ML-IAP cDNA
according to the manufacturer’s instructions.
(e) Subcellular localization of ML-IAP and
ML-IAP RING. MCF7 cells stably transfected
with ML-IAP, ML-IAP RING or vector were
stained with the ML-IAP antiserum and anti-
α- and β-tubulin monoclonal antibody followed
by Cy5-conjugated anti-rabbit antibody and
FITC-conjugated anti-mouse antibody,
respectively. Staining was observed by
confocal microscopy.
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spindles. Formation of mitotic spindles was not affected
by overexpression of ML-IAP as spindle fibers from vector-
transfected cells looked much the same (Figure 1e).
Thus, in contrast to survivin, ML-IAP does not localize
to mitotic spindles.
Apoptosis induced by death receptors and
chemotherapeutic agents is inhibited by ML-IAP 
To determine whether ML-IAP can inhibit apoptosis induced
by death receptors, we expressed Fas, TNFR1, DR4 and
DR5 in MCF7 cells with either vector, or ML-IAP or
known inhibitors of apoptosis. Expression of ML-IAP effi-
ciently blocked apoptosis induced by engagement of Fas,
TNFR1, DR4 and DR5 (Figure 2a). Inhibition of death
receptor-induced apoptosis by ML-IAP was comparable in
potency to that obtained with previously characterized
inhibitors including p35, X-IAP and C-IAP1 (Figure 2a).
Next we determined if ML-IAP could inhibit apoptosis
induced by chemotherapeutic agents. Adriamycin was
chosen as it is readily water soluble, eliminating the
problem of vehicle toxicity, and used widely in clinical
oncology. Adriamycin was a powerful inducer of cell death
in MCF7 cells as evidenced by typical apoptotic morpho-
logical alterations including rounding of cells, membrane
blebbing and eventual detachment from the dish (data
not shown). ML-IAP was as efficient as the positive
control X-IAP in blocking adriamycin-induced apoptosis
(Figure 2b). Additionally, we tested the potent apoptosis-
inducing agent 4-tertiary butylphenol (4-TBP) [33] and
found that ML-IAP effectively blocked 4-TBP-induced cell
death (Figure 2b). These results indicate that ML-IAP is a
potent inhibitor of death-receptor- and chemotherapeutic-
agent-induced apoptosis.
As some IAPs function as caspase inhibitors [23–25], we
investigated whether ML-IAP shares similar caspase-
inhibitory activity. Among the several caspases tested,
ML-IAP was most effective in inhibiting caspase-3, a
downstream effector caspase (Figure 3a). The degree of
inhibition of caspase-3 activity was comparable to that by
C-IAP1 (Figure 3a). In contrast, ML-IAP did not effec-
tively block the activity of caspase-7, a caspase that is
potently inhibited by C-IAP1 (Figure 3a). This difference
in ability to block caspase-7 activity correlated with the
results of binding studies where caspase-7 was found to
bind C-IAP1, but not ML-IAP (Figure 3b). Like the other
IAPs, including X-IAP, C-IAP1 and C-IAP2, ML-IAP did
not inhibit caspases 1, 2, 6 or 8 (data not shown). We also
analyzed the effect of ML-IAP on the activation of cas-
pases by the mitochondrial/cytochrome c pathway that
results in Apaf-1-mediated activation of caspase-9. ML-IAP
inhibited cytochrome-c-mediated activity of caspase-9 in
cytosolic extracts, though not as strongly as C-IAP1
(Figure 3c, upper panel). In addition, immunoprecipita-
tion of ML-IAP and C-IAP1 co-precipitated caspase-9,
confirming physical interaction between the IAPs and the
inhibited caspases (Figure 3c, lower panel). Thus, ML-IAP
can inhibit caspase-3 and caspase-9.
The BIR domain of ML-IAP is responsible for its anti-
apoptotic activity
To identify the region of ML-IAP responsible for inhibiton
of apoptosis, we separately expressed the BIR and the
RING finger domains, with or without adjoining spacer
sequences (Figure 4a,b). Analysis of the ability of these
ML-IAP constructs to inhibit Fas- and TNFR1-induced
apoptosis revealed that an intact BIR domain was necessary
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Figure 2
ML-IAP blocks apoptosis induced by death receptors and adriamycin.
(a) MCF7 cells were transiently transfected with reporter
β-galactosidase, baculovirus p35 or indicated human IAPs and the
death receptors Fas, TNFR1, DR4 or DR5 as indicated. Vector indicates
the vector-only control. (b) MCF7 cells were transiently transfected
with the reporter plasmid pCMV-βgal and either vector control or the
indicated human IAPs before exposure to adriamycin or 4-TBP.
Following transfection, cells were stained with X-gal and apoptosis
assessed as described previously [41]. Percentage apoptosis
represents the mean value from three independent experiments.
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for effective inhibition of cell death (Figure 4c). These
results also showed no functional difference between the
shorter (1–280) and longer (1–298) versions of ML-IAP
(Figure 4c).
A three-dimensional model of the BIR domain of ML-IAP
was built on the basis of sequence similarity by homology
modeling, using the NMR structure coordinates of BIR2 of
X-IAP and BIR3 of C-IAP1 as templates [29,34] (Figure 5).
Threading analysis indicated that the ML-IAP BIR closely
resembled X-IAP BIR2, possessing four α helices and a
three-stranded antiparallel β sheet, as well as correspond-
ing residues that form the hydrophobic core (Figures 5,6b).
The ML-IAP BIR has a carboxy-terminal extension that
shares strong sequence similarity with the carboxy-termi-
nal BIR (BIR3) from C-IAP1 and so this was used as a tem-
plate for modeling the corresponding segment in the
ML-IAP BIR domain (Figures 5,6b). Amino acid residues
C124, C127, H144 and C151 are predicted to coordinate
1362 Current Biology Vol 10 No 21
Figure 3
Inhibition of purified recombinant caspases by ML-IAP. (a) Purified
recombinant caspases 3 and 7, at 4 and 11 nM, respectively, were
incubated in the presence of C-IAP1 (filled circles) and ML-IAP (open
circles) for 20 min at 37°C. The amount of free caspase was
subsequently determined by hydrolysis of Z-DEVD-AFC. rfu, relative
fluorescence units. (b) Binding of GST–C-IAP1 and GST–ML-IAP to
recombinant caspase-7 was done by in vitro pull-down assay and
immunoblotting with anti-caspase-7 antibody. (c) Inhibition of the
cytochrome-c- and dATP-mediated activation of cytosolic 293 extracts.
Upper panel, extracts were treated with 350 nM C-IAP1 or ML-IAP.
Activation was followed online at 37°C and the rate of Ac-DEVD-pNA
hydrolysis determined as the tangent to the activation curves at
600 sec. Lower panel, 293T cells were transiently transfected with
caspase-9 and ML-IAP, C-IAP1 or vector. After 36 h, cells were lysed
in NP-40 lysis buffer and lysates were immunoprecipitated (IP) with an
anti-Myc antibody. Samples were then immunoblotted with an anti-GD
antibody (anti-HIV gp120) and anti-Myc antibody.
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Figure 4
(a) Schematic representation of ML-IAP constructs. Numbers to the
right of the colored boxes designate coding-region boundaries
expressed in a particular construct. (b) Expression of Myc-tagged
ML-IAP constructs was confirmed by western blot analysis using anti-
Myc antibody. (c) Effect of ML-IAP constructs on Fas- and TNFR1-
induced apoptosis. MCF7 cells were transiently transfected with
reporter β-galactosidase, the indicated ML-IAP constructs and Fas or
TNFR1. Apoptosis was assessed as in Figure 2. Percentage apoptosis
represents the mean value from three independent experiments.
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Figure 5
Ribbon diagrams of the structures for the BIR2 domain of X-IAP, BIR3
of C-IAP1 and the modeled structure for BIR of ML-IAP. α Helices are
depicted by cylinders and β sheets by arrows. The side chains of the
residues that chelate zinc (displayed as a sphere) are indicated.
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zinc and stabilize the overall fold [34] (Figure 5). The
surface of the ML-IAP BIR is characterized by a number of
charged residues, the majority of which are well conserved
within the IAP family (Figure 6a,b).
To assess the functional importance of surface amino acid
residues, we mutated several conserved and some non-
conserved residues to alanine (Figure 6c,d). As a control,
we mutated a cysteine that is one of the C2HC zinc-coor-
dinating residues to produce a non-functional BIR domain.
Of the 1 double and 12 single mutants tested, 3 single
mutants showed a substantial decrease in their ability to
inhibit Fas- and TNFR1-induced apoptosis (Figure 6c,d).
Not surprisingly, the most profound loss in inhibitory
activity was observed by mutating the structurally impor-
tant zinc-coordinating cysteine 124 (Figure 6c). In addi-
tion to this residue, mutating aspartates 120 and 138 also
abolished the ability of ML-IAP to inhibit death-receptor-
induced apoptosis (Figure 6c). To test whether caspase
inhibition contributed to the anti-apoptotic mechanism of
ML-IAP, we determined whether apoptosis-inactivating
mutations also abolished the ability to inhibit caspase
activity. Mutations such as the double glutamate 87 and 88
alterations to alanine, which displayed anti-apoptotic
activity comparable to the wild-type molecule, also inhib-
ited caspase activity, whereas the aspartate 120 mutant,
which lost anti-apoptotic activity, showed no caspase-
inhibitory activity (Figure 6e). Therefore, this preliminary
analysis suggests that the anti-apoptotic activity of ML-IAP
correlates with its ability to act as a caspase inhibitor.
ML-IAP is strongly upregulated in melanomas
Given the abundance of ML-IAP mRNA in G361
melanoma cells (Figure 1d), we extended the analysis of
transcript levels to additional melanoma cell lines. All cell
lines examined contained raised amounts of ML-IAP
message (Figure 7a). This was in sharp contrast to normal
human melanocytes (NHEM) where the message was
undetectable (Figure 7a). Examination of endogenous
ML-IAP protein levels in two melanoma cell lines (888,
624) and in melanocytes (NHEM) correlated with expres-
sion of the transcript (Figure 7b).
As the raised levels of ML-IAP could contribute to the
resistance of melanomas to pro-apoptotic chemotherapeu-
tic agents, we investigated the sensitivity of melanoma
cell lines and primary melanocytes to the skin-damaging
agent 4-TBP. Treatment with 4-TBP rapidly induced
Research Paper  ML-IAP, a novel inhibitor of apoptosis Vucic et al. 1363
Figure 6
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Mutational analysis of ML-IAP. (a) Molecular surface presentation
depicting mutations introduced in the BIR domain of ML-IAP. Red
represents acidic, blue basic, and yellow nonpolar amino acid residues
mutated to alanine. Cysteine is shown in pink. (b) Amino acid
sequence alignments of indicated BIR domains. Cylinders represent 
α helices and rectangular arrows β sheets. Mutated amino acids are
labeled as in (a). Alignments were performed as in Figure 1. (c) The
ability of ML-IAP mutants to block Fas- and TNFR1-induced apoptosis.
MCF7 cells were transfected as in Figure 4 and apoptosis assessed
as in Figure 2. Percentage apoptosis represents the mean value from
three independent experiments. (d) Equivalent expression of Myc-
tagged ML-IAP mutants was confirmed by western blot analysis using
mouse anti-Myc antibody. (e) Caspase inhibition by ML-IAP mutants.
Experiments were performed as in Figure 3c.
apoptosis in primary melanocytes, whereas the ML-IAP-
expressing melanoma cell line 888 was resistant, showing
no significant increase in apoptosis over background
(Figure 7c). Similarly, 4-TBP did not induce apoptosis in
another ML-IAP-expressing melanoma cell line, 624 (data
not shown).
Discussion
Viability assays of ML-IAP showed it to be a powerful
inhibitor of apoptosis induced by death receptors and
chemotherapeutic agents. As both death receptor and
intrinsic cell death pathways converge at the point of
caspase activation, we anticipated that ML-IAP might block
caspase activity. Caspase-3 was inhibited by ML-IAP but
caspase-7, a related downstream effector caspase, was only
marginally inhibited under the test conditions. ML-IAP
did, however,  inhibit caspase-9, the initiating caspase in
the mitochondrial pathway responsible for drug-induced
death. As we did not test all known caspases, it is possible
that ML-IAP may inhibit additional members of this
death protease family. IAPs can modulate cell survival by
mechanisms other than caspase inhibition. For instance,
C-IAP1 and C-IAP2 physically interact with TRAF-1 and
TRAF-2 within the TNF receptor complex and may, by
this mechanism, confer resistance to TNF-induced apop-
tosis [7,35]. Our initial studies suggest that ML-IAP does
not bind TRAFs nor is its expression modulated by TNFα
(data not shown). Regardless, ML-IAP may interact with
other yet to be defined non-caspase cellular factors to
inhibit cell death.
IAPs are characterized by the presence of BIR and RING
finger motifs. The BIR region of IAPs is responsible for
anti-apoptotic activity and most protein–protein interac-
tions [16,36,37]. Although ML-IAP is unique in possessing
a single BIR and RING finger, its BIR domain is struc-
turally most related to the BIR2 of X-IAP. Mutations in
residues conserved in the BIR of ML-IAP and BIR2 of
X-IAP (E87,88A and D120A) have the same influence on
anti-apoptotic function [34], implying similar overall struc-
ture of BIR domains. This is also suggested by sequence
comparison and three-dimensional modeling studies,
which revealed strong structural similarity between the
various BIR domains, especially the carboxy-terminal por-
tions of ML-IAP BIR and C-IAP1 BIR3 [29]. This region
has been implicated as essential for inhibition of apoptosis
and for the binding by baculovirus Op-IAP to physiologi-
cal inducers of apoptosis such as Drosophila Hid, Reaper
and Grim [36]. These observations suggest that the
ML-IAP BIR may interact with mammalian counterparts
of the Drosophila cell death proteins. In addition to varia-
tions within the BIR, ML-IAP lacks a sequence upstream
of the BIR2 domain which is important for caspase inhibi-
tion by BIR2 of X-IAP [34]. This difference between
X-IAP and ML-IAP could in part explain the difference in
the caspase-inhibition profile of these two IAPs. 
The existence of multiple IAPs and their differing spatio-
temporal expression patterns suggests an organ-specific
role in promoting cell survival during development and
tissue homeostasis. While X-IAP, C-IAP1 and C-IAP2 are
relatively ubiquitously expressed, NAIP has a more
restricted expression pattern and survivin is expressed
only in fetal and tumor tissues [3]. ML-IAP has a rather
selective expression pattern, as it is predominantly detected
in melanomas and a few other tissues (Figures 1,7). The
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Figure 7
ML-IAP is highly expressed in melanomas.
(a) Analysis of ML-IAP mRNA levels in
melanoma cell lines by RT-PCR. The amount
of RNA was normalized using primers specific
for glyceraldehyde-3-phosphate
dehydrogenase (G3PDH). The origin of the
RNA samples has been described [42,43].
(b) Examination of ML-IAP protein levels in
melanoma cell lines (888, 624) versus
melanocytes (NHEM). Cell lines were lysed,
immunoprecipitated with ML-IAP (ML) or
preimmune (PI) antiserum, subjected to
SDS–PAGE and immunoblotted with ML-IAP
antiserum. A portion of the lysate was
immunoblotted with anti-tubulin antibody
(ICN) to ensure equivalent loading. (c) Cell
lines as indicated were treated for 5 h with the
indicated amounts of 4-TBP. Viability was
assessed by FACS analysis using staining
with propidium iodide and annexin V.
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only other IAP with well-documented expression in
melanomas is survivin [38]. Like survivin, ML-IAP can be
detected in the majority of melanoma cell lines tested but
not in normal melanocytes. Melanoma cell lines with high
levels of ML-IAP are relatively more resistant to apoptotic
stimuli than are normal primary melanocytes. Thus,
ML-IAP might be a critical cellular factor whose increased
expression confers resistance to apoptotic stimuli, thereby
contributing to the pathogenesis and progression of malig-
nant melanomas.
Materials and methods
Isolation of ML-IAP cDNA
We searched the LifeSeq database (Incyte Pharmaceuticals) for
sequences homologous to the BIR region of IAP family members. A
novel sequence related to the BIR of IAPs was identified and several
clones containing full-length or partial sequences were obtained from
Incyte Pharmaceuticals.
Northern blot analysis and chromosomal localization
Adult and fetal human multiple-tissue and cancer cell line northern blots
(Clontech) were hybridized according to the manufacturer’s instruc-
tions with the 32P-labeled probe comprising nucleotides 241–861 of
the ML-IAP open reading frame. Chromosomal localization of ML-IAP
was determined by radiation-hybrid analysis.
Three-dimensional modeling and sequence analysis
The HOMOLOGY/MODELLER module from the InsightII package
(version 98.0; MSI, San Diego, California) was used for molecular con-
struction and display. Threading analysis was carried out using the Pro-
Ceryon software (ProCeryon Biosciences 1999–2000). Amino acid
sequence alignments were performed using ClustalW with gap dis-
tance of 8, open gap penalty of 2.1, extend gap penalty of 0.2 and the
blosum similarity matrix.
Expression vectors, mutagenesis and antibodies
Plasmids expressing β-galactosidase, p35, Myc–C-IAP1, FLAG–Fas,
FLAG–TNFR1, FLAG–DR4, and FLAG—DR5 have been previously
described [39–41]. Myc–ML-IAP and Myc–XIAP were generated by
PCR using custom-made primers encoding an amino-terminal Myc tag.
Amplified products were cloned into the mammalian expression vector
pcDNA3.1. Deletion mutants were generated by PCR with an amino-ter-
minal Myc tag and then subcloned into pcDNA3.1. Site-specific mutants
were generated using Myc-tagged ML-IAP in the pcDNA3.1 back-
ground as a template using the Quick Change site-directed mutagene-
sis kit (Stratagene). C-IAP1, ML-IAP and indicated ML-IAP mutants
were subcloned into pGEX-6P-1 vector (Pharmacia) for expression of
IAPs tagged with glutathione-S-transferase (GST). Antiserum specific
for ML-IAP was raised against a bacterially expressed and purified
amino-terminally His-tagged version of the molecule (Zymed).
Cell cultures, western blot analysis and immunoprecipitation
Human 293T embryonic kidney cells and MCF7 human breast carci-
noma cells were cultured as previously described [40]. The melanoma
cell lines 624 and 888 were generated from metastatic lesions and
maintained as described [42,43]. Human neonatal epidermal
melanocytes, NHEM, were grown according to the supplier’s instruc-
tions (Clonetics). Constructs expressing deletions and mutations of
ML-IAP were transiently transfected in 293T cells using GenePorter
reagent (Gene Therapy Systems) and 24 h later lysed in NP-40 lysis
buffer [17,18]. For western analysis, lysates were resolved by
SDS–PAGE, transferred to Immobilon P membrane (Millipore) and
immunoblotted as described [40]. For immunoprecipitation, 107 cells
were lysed in NP-40 lysis buffer and precleared with nonspecific anti-
body and protein G agarose (Sigma). Lysates were then incubated
with ML-IAP antiserum or preimmmune serum and the resulting
immunocomplexes precipitated with protein G–agarose. Following
extensive washing, the beads were boiled in sample buffer and the
released material subjected to western blot analysis using ML-IAP anti-
serum essentially as described previously.
Immunofluorescence microscopy and ML-IAP stable cell lines
DNAs encoding ML-IAP and ML-IAP RING were cloned into the
pCEP4 vector (Invitrogen) and stable clones were made in MCF7 cells
using standard molecular biology techniques. MCF7 cells stably trans-
fected with ML-IAP, ML-IAP RING or vector were treated with 10 µM
taxol (Sigma), fixed in methanol and stained with the ML-IAP antiserum
or anti-α and -β-tubulin monoclonal antibody (Sigma). Immunodetection
of ML-IAP and tubulin, respectively, was carried out with Cy5-conju-
gated anti-rabbit antibody and FITC-conjugated anti-mouse antibody
(Jackson Immunoresearch). Cells were examined and photographed
using confocal microscopy (Leica SP).
Protein purification and caspase inhibition and binding assays
Purified recombinant caspases and recombinant GST–IAPs were
expressed and isolated as previously described [44,45]. Cytosolic
extracts of HEK293 cells were also prepared as previously described
[23,46]. The IAPs were tested for their ability to inhibit purified recom-
binant caspases by adding a range of IAP concentrations to the cas-
pases of interest in IAP buffer (10 mM Pipes, 100 mM NaCl, 0.1%
Chaps, 10% sucrose, 20 mM β-mercaptoethanol pH 7.2). The mixture
was incubated at 37°C for 20 min before addition of Z-DEVD-AFC
(Enzyme System Products) to a final concentration of 100 µM. The
hydrolysis of the substrate was followed as the increase in fluores-
cence at 500 nm upon excitation at 405 nm. The activity was deter-
mined as the initial rate of hydrolysis. For in vitro pull-down assay,
1.5 µM of purified recombinant caspase-7 was mixed with 0.6 µM of
the GST–IAP of interest in IAP buffer and incubated at 37°C for
30 min. After incubation, glutathione–sepharose (Pharmacia) beads
were added to the mixture for 1 h at 4°C followed by washing. The pro-
teins bound to the beads were resolved by SDS–PAGE and western
blot analysis was performed using mouse anti-caspase-7 (Pharmingen).
The ability of the IAPs to inhibit the activation of cytosolic extracts by
cytochrome c/dATP was tested in an online assay. Briefly, IAPs were
added to 50 µl cytosolic extract, containing 400 µM Ac-DEVD-pNA
(Bachem), to a final concentration of 350 nM. The activation was then
initiated by addition of cytochrome c and dATP to a final concentration
of 10 µM and 1 mM, respectively. The activation reaction was followed
online as the increase in absorbance at 405 nm over time using a Mol-
ecular Devices SpectraMax 340 microplate reader at 37°C. The
amount of active caspase-3 at 600 sec was determined as the tangent
to the activation curve at this time point.
Apoptosis assays
MCF7 cells were transiently transfected with 0.2 µg of the reporter
plasmid pCMV-βgal plus 0.2 µg of plasmid encoding Fas, TNFR1, DR4
or DR5 and 1.6 µg of plasmid encoding vector, baculovirus P35 or
indicated human IAPs. For adriamycin or 4-TBP treatment, MCF7 cells
were transiently transfected with the reporter plasmid pCMV-βgal and
control vector or indicated human IAPs. Four hours following transfec-
tion, adriamycin (doxorubicin, Sigma) or 4-TBP (Aldrich) was added to
the media at the indicated concentrations. Apoptosis was assayed 16 h
later as described [41]. Melanoma cell lines (888, 624) or melanocytes
(NHEM cells) were treated for 5 h with the indicated amounts of 4-TBP
and viability assessed by FACS analysis using staining with propidium
iodide and annexin V (Clontech).
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